Protagonist Therapeutics (PTGX) Total Debt (2018 - 2023)

Protagonist Therapeutics has disclosed Total Debt across 6 years of filings, most recently posting $10000.0 for Q2 2023.

• Total Debt for Q2 2023 came in at $10000.0, down 87.5% year-over-year; the trailing twelve-month figure through Jun 2023 was $10000.0 (down 87.5% YoY), and the FY2022 annual result was $69000.0, down 92.32% from the prior year.
• Total Debt came in at $10000.0 for Q2 2023 at Protagonist Therapeutics, down from $22000.0 in the prior quarter.
• In the past five years, Total Debt ranged from a high of $11.4 million in Q2 2021 to a low of $10000.0 in Q2 2023.
• The 5-year median for Total Debt is $1.0 million (2019), against an average of $1.8 million.
• Across the five-year window, Total Debt jumped 1036.19% in 2021 and plunged 99.3% in 2022, its largest moves.
• Protagonist Therapeutics' Total Debt stood at $1.3 million in 2019, then surged by 116.48% to $2.7 million in 2020, then sank by 67.09% to $899000.0 in 2021, then slumped by 92.32% to $69000.0 in 2022, then plunged by 85.51% to $10000.0 in 2023.
• The last three Total Debt figures came in at $10000.0 (Q2 2023), $22000.0 (Q1 2023), and $69000.0 (Q4 2022), per Business Quant data.